Equity Details
Price & Market Data
Price: $1.92
Daily Change: -$0.02 / 1.04%
Daily Range: $1.88 - $1.98
Market Cap: $321,838,464
Daily Volume: 1,808,463
Performance Metrics
1 Week: -2.54%
1 Month: -3.52%
3 Months: 10.98%
6 Months: 14.29%
1 Year: 149.7%
YTD: -18.30%
About Palisade Bio, Inc. (PALI)
Comprehensive analysis of Palisade Bio, Inc. (PALI). Currently at 1.92, with a daily change of -$0.02 / 1.04%. Market cap: 321,838,464. Evaluate its performance over YTD, 1-month, and 6-month periods.
Company Details
Employees: 14
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.